ID: ALA5191364

Max Phase: Preclinical

Molecular Formula: C26H33FN4O2

Molecular Weight: 452.57

Representations

Canonical SMILES:  C[C@@H]1CCCN1Cc1ccc(-c2cnc(N)c3c2CCN(C2CCC(O)CC2)C3=O)cc1F

Standard InChI:  InChI=1S/C26H33FN4O2/c1-16-3-2-11-30(16)15-18-5-4-17(13-23(18)27)22-14-29-25(28)24-21(22)10-12-31(26(24)33)19-6-8-20(32)9-7-19/h4-5,13-14,16,19-20,32H,2-3,6-12,15H2,1H3,(H2,28,29)/t16-,19?,20?/m1/s1

Standard InChI Key:  QIGLCSOIUAUGES-PBPGXSGUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 452.57

Molecular Weight (Monoisotopic): 452.2588

AlogP: 3.76

#Rotatable Bonds: 4

Polar Surface Area: 82.69

Molecular Species: BASE

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.72

CX LogP: 3.48

CX LogD: 2.14

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.74

Np Likeness Score: -0.50

References

1. Witten MR, Wu L, Lai CT, Kapilashrami K, Pusey M, Gallagher K, Chen Y, Yao W..  (2022)  Inhibition of ALK2 with bicyclic pyridyllactams.,  55  [PMID:34780900] [10.1016/j.bmcl.2021.128452]

Source

Source(1):

• Scientific Literature